Cosmo Bio CoTSE:3386 -0.55%73 EBITDA Margin % is 4.25% as of Dec. 2025, which is 46% below its 10-year median of 7.94. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,246.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 50.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cosmo Bio Co's EBITDA for the
six
months ended in Dec. 2025 was 円228 Mil. Cosmo Bio Co's Revenue for the
six
months ended in Dec. 2025 was 円5,364 Mil. Therefore, Cosmo Bio Co's EBITDA margin for the quarter that ended in Dec. 2025 was 4.25%.
Cosmo Bio Co (TSE:3386) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cosmo Bio Co EBITDA Margin % Related Terms
Cosmo Bio Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a EBITDA Margin % of 4.25% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cosmo Bio Co and its competitors. This is 46% below median its historical median of 7.94. Over the past decade, Cosmo Bio Co's EBITDA Margin % has ranged from 5.03 to 14.62. According to the industry distribution chart, Cosmo Bio Co ranks #100 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 49%.
Is Cosmo Bio Co's EBITDA Margin % too high?
Cosmo Bio Co's current EBITDA Margin % of 4.25% is 46% below median its 10-year median of 7.94. Over the past 10 years, this metric has ranged from a low of 5.03 to a high of 14.62. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Cosmo Bio Co's value of 4.25% is 18.3% below this industry median. Based on the distribution chart, Cosmo Bio Co ranks #100 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #100 out of 204 companies for EBITDA Margin %. This puts Cosmo Bio Co in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Cosmo Bio Co's value of 4.25% is 18.3% below this benchmark. Historically, Cosmo Bio Co's own EBITDA Margin % has ranged from 5.03 to 14.62 over the past decade. While the company's 10-year median is 7.94 vs. the industry median of 5.20, Cosmo Bio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo Bio Co's current EBITDA Margin % of 4.25% is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cosmo Bio Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo Bio Co's current EBITDA Margin % is 4.25%, which is 46% below median its own 10-year median of 7.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,246.90, compared to a current price of 円1,262.00 — trading 1.2% above its estimated fair value. The current EBITDA Margin % is 4.25%, which is 46% below median its 10-year median of 7.94 and 18.3% below the Medical Diagnostics & Research industry median of 5.20. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current EBITDA Margin % is 4.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,262.00 is trading 1.2% above its estimated GF Value™ of 円1,246.90.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
EBITDA Margin %: 4.25% (46% below median its 10-year median of 7.94)
GF Value™: 円1,246.90 vs. price of 円1,262.00 (1.2% above fair value)
Industry Position: 18.3% below the Medical Diagnostics & Research median (#100 of 204)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
